1. Home
  2. NSRX vs SCLX Comparison

NSRX vs SCLX Comparison

Compare NSRX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$2.78

Market Cap

53.5M

Sector

Health Care

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$7.85

Market Cap

59.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSRX
SCLX
Founded
2019
2011
Country
Israel
United States
Employees
N/A
30
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.5M
59.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NSRX
SCLX
Price
$2.78
$7.85
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$20.50
N/A
AVG Volume (30 Days)
125.0K
28.0K
Earning Date
03-20-2026
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.60
$0.18
52 Week High
$9.99
$34.27

Technical Indicators

Market Signals
Indicator
NSRX
SCLX
Relative Strength Index (RSI) 25.26 40.52
Support Level N/A $7.73
Resistance Level $6.39 $9.00
Average True Range (ATR) 0.46 0.68
MACD -0.19 0.08
Stochastic Oscillator 0.77 6.25

Price Performance

Historical Comparison
NSRX
SCLX

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: